Complications of Lung Cancer Treatment

ABSTRACT

In most cases lung cancer is incurable, but treatment is prolonging life for many and sustaining quality of life. Inevitably, disease-related symptoms develop with disease progression, and it can be difficult to differentiate these from treatment-induced complications. This is particularly true for pulmonary complications because tumor progression occurs most frequently in the lungs, and separating the effects of the disease from those induced by treatment (chemotherapy, radiotherapy) is often very difficult. This chapter identifies the main complications around surgical resection of lung cancer, highlighting the importance of expert postoperative care. For palliative treatments such as radiotherapy and chemotherapy, complications are related to the planned intensity of proposed therapy, the performance status of the patients, and patient age. Treatment of the elderly sufferer, now representing almost 50% of new cases, is poorly researched, but therapy-related complications are commoner in those aged over 70 years by ~20% when compared with their younger counterparts. Even during palliative care great attention has to be taken to minimize side effects of commonly used medications.

KEYWORDS

Complications - chemotherapy - radiation therapy - surgery - palliative care

REFERENCES

• 1 Ries L AG, Eisner M P, Kosary C L et al.. SEER Cancer Statistics review 1975–2000. http://seer.cancer.gov/csr/1975_2000
• 2 Gridelli C, Perrone F, Monfardini S. Lung cancer in the elderly.  Eur J Cancer. 1997;  33 2313-2314
• 3 Spiro S G, Gower N H, Evans M T et al.. Recruitment of patients with lung cancer into a randomised clinical trial: experience at two centres.  Thorax. 2000;  55 463-465
• 4 Jatoi A, Hillman S, Stella P et al.. Should elderly non-small cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.  J Clin Oncol. 2005;  23 9113-9119
• 5 Martin-Ucar A E, Waller D A, Atkins J L et al.. The beneficial effects of specialist thoracic surgery on the resection rate for non-small cell lung cancer.  Lung Cancer. 2004;  46 227-232
• 6 Arozullah A M, Daley J, Henderson W G, Khuri S F. Multifactorial risk index for predicting postoperative respiratory failure in men after major non-cardiac surgery.  Ann Surg. 2000;  232 242-250
• 7 Arozullah A M, Khuri S F, Henderson W G, Daley J. Development and validation of a multifactorial risk index for predicting postoperative pneumonia after major noncardiac surgery.  Ann Intern Med. 2001;  135 847-857
• 8 Rostad H, Strand T-E, Naalsuund A, Talleraas O, Norstein J. Lung cancer surgery: the first 60 days: a population-based study.  Eur J Cardiothorac Surg. 2006;  29 824-828
• 9 Bernard A, Deschamps C, Allen M S et al.. Pneumonectomy for malignant disease: factors affecting early morbidity and mortality.  J Thorac Cardiovasc Surg. 2001;  121 1076-1082
• 10 Harpole D H, Liptay M J, DeCamp M M et al.. Prospective analysis of pneumonectomy: risk factors for major morbidity and cardiac dysrhythmias.  Ann Thorac Surg. 1996;  61 977-982
• 11 Ferguson M K, Reeder L B, Mick R. Optimizing selection of patients for major lung resection.  J Thorac Cardiovasc Surg. 1995;  109 275-283
• 12 Yildizeli B, Fadel E, Mussot S et al.. Morbidity, mortality, and long-term survival after sleeve lobectomy for non-small cell lung cancer.  Eur J Cardiothorac Surg. 2007;  31 95-102
• 13 Van Schil P, Van Meerbeck J, Kramer G et al.. Morbidity and mortality in the surgery arm of EORTC 08941 Trial.  Eur Resp J. 2005;  26 192-197
• 14 Gilligan D, Nicholson M, Smith I et al.. Preoperative chemotherapy in patients with respectable non-small cell lung cancer: results of the MRC LU22/NVALT 2/EORTC 08012 multicentre randomised trial and update of systematic review.  Lancet. 2007;  369 1929-1937
• 15 De Pauw R, van Meerbeeck J P. Neoadjuvant chemotherapy in the treatment of non small cell lung cancer.  Curr Opin Oncol. 2007;  19 92-97
• 16 Leo F, Solli P, Veronesi G, Radice D et al.. Does chemotherapy increase the risk of respiratory complications after pneumonectomy?.  J Thorac Cardiovasc Surg. 2006;  132 519-523
• 17 Venuta F, Anile M, Diso D, Ibrahim M. Operative complications and early mortality after induction therapy for lung cancer.  Eur J Cardiothorac Surg. 2007;  31 714-717
• 18 Mansour Z, Kochetkova E A, Ducrocq X et al.. Induction chemotherapy does not increase the operative risk of pneumonectomy!.  Eur J Cardiothorac Surg. 2007;  31 181-185
• 19 Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.  BMJ. 1995;  311 899-909
• 20 Arriagada R, Bergman B, Dumant A, Le Chevalier T, Pignon J, Vansteenkiste J. Cisplatin-based adjuvant chemotherapy in patients with completely resected non small-cell lung cancer.  N Engl J Med. 2004;  350 351-360
• 21 Waller D, Peake M D, Stephens R J. Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial.  Eur J Cardiothorac Surg. 2004;  26 173-182
• 22 Belda J, Calvacanti M, Ferrer M et al.. Bronchial colonisation and postoperative respiratory infections in patients undergoing lung cancer surgery.  Chest. 2005;  Sp; 128(3) 1571-1579
• 23 Cabello H, Torres A, Celis R et al.. Bacterial colonisation of distal airways in healthy subjects and chronic lung disease: a bronchoscopic study.  Eur Respir J. 1997;  10 1137-1144
• 24 Ioanas M, Angrill J, Baldo X et al.. Bronchial bacterial colonisation in patients with respectable lung cancer.  Eur Respir J. 2002;  19 326-332
• 25 Belda J, Cavalcanti M, Ferrer M et al.. Bronchial colonisation and postoperative respiratory infections in patients undergoing lung cancer surgery.  Chest. 2005;  128 1571-1579
• 26 Pauwels R A, Buist A S, Calverley P M et al.. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease(GOLD) Workshop summary.  Am J Respir Crit Care Med. 2001;  163 1256-1276
• 27 Soler N, Ewig S, Torres A et al.. Airway inflammation and bronchial microbial patterns in patients with stable chronic obstructive pulmonary disease.  Eur Respir J. 1999;  14 1015-1022
• 28 Licker M J, Widikker I, Robert J et al.. Operative mortality and respiratory complications after lung resection for cancer: impact of chronic obstructive pulmonary disease and time trends.  Ann Thorac Surg. 2006;  81 1830-1838
• 29 Volpino P, Cangemi R, Fiori E et al.. Risk of mortality from cardiovascular and respiratory causes in patients with chronic obstructive pulmonary disease submitted to follow-up after lung resection for non-small cell lung cancer.  J Cardiovasc Surg (Torino). 2007;  48 375-383
• 30 Sonobe M, Nakagawa M, Ichinose M et al.. Analysis of risk factors in bronchopleural fistula after pulmonary resection for primary lung cancer.  Eur J Cardiothorac Surg. 2000;  18 519-523
• 31 Deschamps C, Bernard A, Nichols F C et al.. Empyema and bronchopleural fistula after pneumonectomy: factors affecting incidence.  Ann Thorac Surg. 2001;  72 243-247
• 32 Myrdal G, Valtysdottir M, Lambe M, Stahle E. Quality of life following lung cancer surgery.  Thorax. 2003;  58 194-197
• 33 Win T, Sharples L, Wells F C, Ritchie A J, Munday H, Laroche C M. Effect of lung cancer surgery on quality of life.  Thorax. 2005;  60 234-238
• 34 Sarna L, Padilla G, Holmes C, Tashkin D, Brecht M L, Evangelista L. Quality of life of long-term survivors of non-small cell ling cancer.  J Clin Oncol. 2002;  20 2920-2929
• 35 Tyldesley S, Boyd C, Schulze K, Walker H, Mackillop W J. Estimating the need for radiotherapy for lung cancer: an evidence-based, epidemiologic approach.  Int J Radiat Oncol Biol Phys. 2001;  49 973-985
• 36 Kong F M, Ten Haken R, Eisbruch A, Lawrence T S. Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis.  Semin Oncol. 2005;  32(2, Suppl 3) S42-S54
• 37 Lopez Rodriguez M, Cerezo Padellano L. Toxicity associated to radiotherapy treatment in lung cancer patients.  Clin Transl Oncol. 2007;  9 506-512
• 38 Giangreco A, Groot K R, Janes S M. Lung cancer and lung stem cells: strange bedfellows?.  Am J Respir Crit Care Med. 2007;  175 547-553 , Epub 2006 Dec 7
• 39 Van der Kogel A J, Ang K K. Complications related to radiotherapy. In: Peckham M, Pinedo H, Veronesi U Oxford Textbook of Oncology. Oxford; Oxford University Press 1995: 2295-2306
• 40 Movsas B, Raffin T A, Epstein A H et al.. Pulmonary radiation injury.  Chest. 1997;  111 1061-1076
• 41 Davis S D, Yankelevitz D F, Henschke C I. Radiation effects on the lung: clinical features, pathology, and imaging findings.  AJR Am J Roentgenol. 1992;  159 1157-1164
• 42 Van Houtte P, Mornex P. Radiotherapy of non-small-cell and small-cell and SCLC. In: Spiro SG Carcinoma of the Lung. European Respiratory Monograph, Vol 1. Leeds, UK; Maney Publishers 1995: 241-268
• 43 Bate D, Guttemann R J. Changes in the lung and pleura following 2-million volt therapy for carcinoma of the breast.  Radiology. 1957;  69 372-382
• 44 Ross W M. Radiotherapeutic and radiological aspects of radiation fibrosis of the lungs.  Thorax. 1956;  11 241-246
• 45 Libshitz H I, Southard M E. Complications of radiation therapy: the thorax.  Semin Roentgenol. 1974;  9 41-49
• 46 Roswit B, White D C. Severe radiation injuries of the lung.  AJR Am J Roentgenol. 1977;  129 127-136
• 47 Bachman A L, Macken K. Pleural effusions following supervoltage radiation for breast carcinoma.  Radiology. 1959;  72 699-709
• 48 Libshitz H I, Shuman L S. Radiation-induced pulmonary change: CT findings.  J Comput Assist Tomogr. 1984;  8 15-19
• 49 Glazer H S, Lee J KT, Levitt R G et al.. Radiation fibrosis: differentiation from recurrent tumor by MR imaging.  Radiology. 1985;  156 721-726
• 50 Kataoka M, Kawamura M, Itho H et al.. Ga-67 citrate scintigraphy for the early detection of radiation pneumonitis.  Clin Nucl Med. 1992;  17 27-31
• 51 Watchie J, Coleman C N, Raffin T A et al.. Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease.  Int J Radiat Oncol Biol Phys. 1987;  13 517-524
• 52 Lokich J J, Brass H, Eberly F E et al.. The pulmonary effect of mantle irradiation in patients with Hodgkin's disease.  Radiology. 1973;  108 397-402
• 53 Uitterhoeve A L, Koolen M G, van Os R M et al.. Accelerated high-dose radiotherapy alone or combined with either concomitant or sequential chemotherapy; treatments of choice in patients with non-small cell lung cancer.  Radiat Oncol. 2007;  2 27
• 54 Onishi H, Kuriyama K, Yamaguchi M et al.. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: a good local response but no good survival due to radiation pneumonitis.  Lung Cancer. 2003;  40 79-84
• 55 Kouroussis C, Mavroudis D, Kakolyris S et al.. High incidence of pulmonary toxicity of weekly docetaxel and gemcitabine in patients with non-small cell lung cancer: results of a dose-finding study.  Lung Cancer. 2004;  44 363-368
• 56 Nagata Y, Matsuo Y, Takayama K et al.. Current status of stereotactic body radiotherapy for lung cancer.  Int J Clin Oncol. 2007;  12 3-7 , Epub 2007 Feb 25
• 57 Li X, Zhang P, Mah D, Gewanter R, Kutcher G. Novel lung IMRT planning algorithms with nonuniform dose delivery strategy to account for respiratory motion.  Med Phys. 2006;  33 3390-3398
• 58 Liu R, Buatti J M, Howes T L, Dill J, Modrick J M, Meeks S L. Optimal number of beams for stereotactic body radiotherapy of lung and liver lesions.  Int J Radiat Oncol Biol Phys. 2006;  66 906-912 , Epub 2006 Aug 14
• 59 Rancati T, Ceresoli G L, Gagliardi G, Schipani S, Cattaneo G M. Factors predicting radiation pneumonitis in lung cancer patients: a retrospective study.  Radiother Oncol. 2003;  67 275-283
• 60 Jenkins P, D'Amico K, Benstead K, Elyan S. Radiation pneumonitis following treatment of non-small-cell lung cancer with continuous hyperfractionated accelerated radiotherapy(CHART).  Int J Radiat Oncol Biol Phyl. 2003;  56 360-366
• 61 Yorke E D, Jackson A, Rosenzweig K E et al.. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy.  Int J Radiat Oncol Biol Phys. 2002;  54 329-339
• 62 Fu X L, Huang H, Bentel G et al.. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V(30) and transforming growth factor beta.  Int J Radiat Oncol Biol Phys. 2001;  50 899-908
• 63 Gross N J. Pulmonary effects of radiation therapy.  Ann Intern Med. 1977;  86 81-92
• 64 Wang J Y, Chen K Y, Wang J et al.. Outcome and prognostic factors for patients with non-small-cell lung cancer and severe radiation pneumonitis.  Int J Radiat Oncol Biol Phys. 2002;  54 735-741
• 65 Rubin O, Casarett G W. Clinical Radiation Pathology. Philadelphia; WB Saunders 1968: 423-470
• 66 Bennett D E, Million R R, Ackerman L V. Bilateral radiation pneumonitis: a complication of the radiotherapy of bronchogenic carcinoma.  Cancer. 1969;  23 1001-1018
• 67 Coggle J E, Lambert B E, Moores S R. Radiation effects in the lung.  Environ Health Perspect. 1986;  70 261-291
• 68 Crestani B, Valeyre D, Roden S et al.. Bronchiolitis obliterans organising pneumonia syndrome primed by radiation therapy to the breast.  Am J Respir Crit Care Med. 1998;  158 1929-1935
• 69 Martin C, Romero S, Sanchez-Paya J et al.. Bilateral lymphocytic alveolitis: a common reaction after unilateral thoracic irradiation.  Eur Respir J. 1999;  13 727-732
• 70 Braakhuis B J, Tabor M P, Kummer J A et al.. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications.  Cancer Res. 2003;  63 1727-1730
• 71 Johnson B E, Cortazar P, Chute J P. Second lung cancers in patients successfully treated for lung cancer.  Semin Oncol. 1997;  24 492-499
• 72 Van Bodegom P C, Wagenaar S S, Corrin B et al.. Second primary lung cancer: Importance of long term follow up.  Thorax. 1989;  44 788-793
• 73 Sugimura H, Watanabe S, Tsugane S et al.. Case-control study on histologically determined multiple primary lung cancer.  J Natl Cancer Inst. 1987;  79 435-441
• 74 Mathisen D J, Jensik R J, Faber L P, Kittle C F. Survival following resection for second and third primary lung cancers.  J Thorac Cardiovasc Surg. 1984;  88 502-510
• 75 Deschamps C, Pairolero P C, Trastek V F, Payne W S. Multiple primary lung cancers: results of surgical treatment.  Ann Thorac Cardiovasc Surg. 1990;  99 769-777 discussion 777-778
• 76 Tucker M A, Coleman C N, Cox R S et al.. Risk of second cancers after treatment for Hodgkin's disease.  N Engl J Med. 1988;  318 76-81
• 77 Kirova Y M, Feuilhade F, Calitchi E et al.. Radiation-induced sarcoma after breast cancer: apropos of 8 cases and review of the literature.  Cancer Radiother. 1998;  2 381-386
• 78 Van der Kogel A J. Radiation response and tolerance of normal tissues. In: Steel GG Basic Clinical Radiobiology. London, UK; Arnold 1997: 30-39
• 79 Stewart J R, Fajardo L F. Radiation-induced heart disease: an update.  Prog Cardiovasc Dis. 1984;  27 173-194
• 80 Schultz-Hector S. Heart. In: Scherer E, Streffer C, Trott KR Radiopathology of Organs and Tissues. Berlin; Springer-Verlag 1991: 347-368
• 81 Brosius F C, Waller B F, Roberts W L. Analysis of 16 young (aged 15–33 years) necropsy patients who received over 3500 rads to the heart.  Am J Med. 1981;  70 519-530
• 82 PORT Meta-analysis Trialists Group . Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials.  Lancet. 1998;  352 257-263
• 83 Dautzenberg B, Arriagada R, Chammard A B et al.. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma.  Cancer. 1999;  86 265-273
• 84 Van der Kogel A J, Ang K K. Complications related to radiotherapy. In: Peckham M, Pinedo H, Veronesi U Oxford Textbook of Oncology. Oxford; Oxford University Press 1995: 2295-2306
• 85 Macbeth F R, Wheldon T E, Girling D J et al.. Radiation myelopathy: estimates of risk in 1048 patients in three randomised trials of palliative radiotherapy for non-small cell lung cancer. The Medical Research Council Lung Cancer Working Party.  Clin Oncol (R Coll Radiol). 1996;  8 176-181
• 86 Cullen M H, Billingham L J, Woodroffe C M et al.. Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lung cancer: Effects on survival and quality of life.  J Clin Oncol. 1999;  17 3188-3194
• 87 Spiro S G, Rudd R M, Souhami R L et al.. Chemotherapy versus best supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.  Thorax. 2004;  59 828-836
• 88 Schiller J H, Harrington D, Belani C P et al.. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer.  N Engl J Med. 2002;  346 92-98
• 89 Rudd R M, Gower N H, Spiro S G et al.. Gemcitabine plus carboplatin versus mitomycin, ifosfamide, and cisplatin in patients with stage IIIB or IV non-small cell lung cancer: a phase III randomised study of the London Lung Cancer Group.  J Clin Oncol. 2005;  23 142-153
• 90 Dimitroulis J, Stathopoulos G P. Evolution of non small cell lung cancer chemotherapy [review].  Oncol Rep. 2005;  13 923-930
• 91 Ruckdeschel J C, Finkelstein D M, Mason B A et al.. Chemotherapy for metastatic non-small-cell bronchogenic carcinoma: EST 2575, generation V–a randomized comparison of four cisplatin-containing regimens.  J Clin Oncol. 1985;  3 72-79
• 92 Gridelli C, Ardizzoni A, Le Chevalier T et al.. Treatment of advanced non-small cell lung cancer patients with ECOG performance status 2: results of an European Expert Panel.  Ann Oncol. 2004;  15 419-426
• 93 Georgoulias V, Papadakis E, Alexopoulos A et al.. Platinum-based and non-platinum based chemotherapy in advanced non-small cell lung cancer: a randomised multicentre trial.  Lancet. 2001;  357 1478-1484
• 94 Kosmidis P, Mylonakis N, Nicolaides C et al.. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomised trial.  J Clin Oncol. 2002;  20 3578-3585
• 95 Alberola V, Camps C, Provencio M et al.. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small cell lung cancer: a Spanish Lung Cancer Group phase III randomised trial.  J Clin Oncol. 2003;  21 3207-3213
• 96 Gridelli C, Gallo C, Shepherd F A et al.. Gemcitabine plus vinorelbine compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada-Clinical Trials Group.  J Clin Oncol. 2003;  21 3025-3034
• 97 Gridelli C, Langer C, Maione P, Rossi A, Schild S E. Lung cancer in the elderly.  J Clin Oncol. 2007;  25 1898-1907
• 98 Elderly Lung Cancer Vinorelbine Italian Study Group . Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer.  J Natl Cancer Inst. 1999;  91 66-72
• 99 Cullen M, Steven N, Billingham L et al.. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.  N Engl J Med. 2005;  353 988-998
• 100 Morittu L, Earl H M, Souhami R L et al.. Patients at risk of chemotherapy-associated toxicity in small cell lung cancer.  Br J Cancer. 1989;  59 801-804
• 101 Carnes P, White D A. Drugs and the lungs. In: Albert RK, Spiro SG, Jett JR Clinical Respiratory Medicine. 3rd ed. Philadelphia; Elsevier 2008
• 102 Ramanathan R K, Reddy V V, Holbert J M, Belani C P. Pulmonary infiltrates following administration of paclitaxel.  Chest. 1996;  110 289-292
• 103 Bonomi P, Faber L P, Warren W et al.. Postoperative bronchopulmonary complications in stage III lung cancer patients treated with preoperative paclitaxel-containing chemotherapy and concurrent radiation.  Semin Oncol. 1997;  24(4 Suppl 12) S12-123-S12-129
• 104 Dimopoulou I, Efstathiou E, Samakovli A et al.. A prospective study on lung toxicity in patients treated with gemcitabine and carboplatin: clinical, radiological and functional assessment.  Ann Oncol. 2004;  15 1250-1255
• 105 Carron P L, Cousin L, Caps T et al.. Gemcitabine-associated diffuse alveolar hemorrhage.  Intensive Care Med. 2001;  27 1554
• 106 Vansteenkiste J F, Bomans P, Verbeken E K et al.. Fatal pulmonary veno-occlusive disease possibly related to gemcitabine.  Lung Cancer. 2001;  31 83-85
• 107 Forsythe B, Faulkner K. Clinical experience with gefitinib (Iressa,ZD1839): an overview of safety and tolerability.  Lung Cancer. 2003;  41(Suppl 2) S70-S71
• 108 Gurjal A, An T, Valdivieso M, Kalemkerian G P. Etoposide-induced pulmonary toxicity.  Lung Cancer. 1999;  26 109-112
• 109 Inoue A, Saijo Y, Maemondo M et al.. Severe acute interstitial pneumonia and gefitinib.  Lancet. 2003;  361 137-139
• 110 Shepherd F A, Rodrigues Pereira J, Ciuleanu T et al.. Erlotinib in previously treated non–small-cell lung cancer.  N Engl J Med. 2005;  353 123-132
• 111 Tassinari D, Sartori S, Gianni L et al.. Is acute dyspnoea a rare side effect of vinorelbine?.  Ann Oncol. 1997;  8 503-504
• 112 Verweij J, van Zanten T, Souren T et al.. Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis.  Cancer. 1987;  60 756-761
• 113 Rivera M P, Kris M G, Gralla R J, White D A. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy.  Am J Clin Oncol. 1995;  18 245-250
• 114 Raderer M, Kornek G, Hejna M et al.. Acute pulmonary toxicity associated with high-dose vinorelbine and mitomycin C.  Ann Oncol. 1996;  7 973-975
• 115 Chang A YC, Kuebler J P, Pandya K J et al.. Pulmonary toxicity induced by mitomycin C is highly responsive to glucocorticoids.  Cancer. 1986;  57 2285-2290
• 116 Torra R, Poch E, Torras A et al.. Pulmonary hemorrhage as a clinical manifestation of hemolytic-uremic syndrome associated with mitomycin C therapy.  Chemotherapy. 1993;  39 453-456
• 117 Castro M, Veeder M H, Mailliard J A, Tazelaar H D, Jett J R. A prospective study of pulmonary function in patients receiving mitomycin.  Chest. 1996;  109 939-944
• 118 Soares M, Darmon M, Salluh J IF et al.. Prognosis of lung cancer patients with life – threatening complications.  Chest. 2007;  131 840-846
• 119 http://www.who.int/cancer/palliative/en/ WHO guidelines: Cancer pain relief. 2nd ed. Geneva; World Health Organisation 1996
• 120 Donnelly S, Walsh D. The symptoms of advanced cancer.  Semin Oncol. 1995;  22(2, Suppl 3) 67-72
• 121 McCaffrey M, Beebe A. Pain: Clinical Manual for Nursing Practice. St. Louis; CV Mosby 1989
• 122 Corner J. Innovative approaches in symptom management.  Eur J Cancer Care (Engl). 1995;  4 145-146
• 123 Cooley M E. Symptoms in adults with lung cancer: a systematic research review.  J Pain Symptom Manage. 2000;  19 137-153
• 124 O'Driscoll M, Corner J, Bailey C. The experience of breathlessness in lung cancer.  Eur J Cancer Care (Engl). 1999;  8 37-43
• 125 Smith E L, Hann D M, Ahles T A et al.. Dyspnea, anxiety, body consciousness and quality of life in patients with lung cancer.  J Pain Symptom Manage. 2001;  21 323-329
• 126 Muers M F. Opioids for dyspnoea.  Thorax. 2002;  57 922-923
• 127 Lai Y L, Chan C W, Lopez V. Perceptions of dyspnea and helpful interventions during the advanced stage of lung cancer: Chinese patients' perspectives.  Cancer Nurs. 2007;  30 E1-E8
• 128 Hately J, Laurence V, Scott A, Baker R, Thomas P. Breathlessness clinics within specialist palliative care settings can improve the quality of life and functional capacity of patients with lung cancer.  Palliat Med. 2003;  17 410-417
• 129 Corner J, Plant H, A'Hern R, Bailey C. Non-pharmacological intervention for breathlessness in lung cancer.  Palliat Med. 1996;  10 299-305
• 130 Dorman S, Byrne A, Edwards A. Which measurement scales should we use to measure breathlessness in palliative care? A systematic review.  Palliat Med. 2007;  21 177-191 , Epub 2007 Mar 15
• 131 Levin D N, Cleeland C S, Dar R. Public attitudes toward cancer pain.  Cancer. 1985;  56 2337-2339
• 132 Hoffman A J, Given B A, von Eye A, Gift A G, Given C W. Relationships among pain, fatigue, insomnia, and gender in persons with lung cancer.  Oncol Nurs Forum. 2007;  34 785-792
• 133 World Health Organization. .WHO's Pain Relief Ladder. http://www.who.int/cancer/palliative/painladder/en/index.html Accessed April 1, 2008
• 134 Larue F, Colleau S M, Brasseur L et al.. Multicentre study of cancer pain and its treatment in France.  BMJ. 1995;  310 1034-1037
• 135 Brown J, Thorpe H, Napp V et al.. Assessment of quality of life in the supportive care setting of the big lung trial in non-small-cell lung cancer.  J Clin Oncol. 2005;  23(30) 7417-7427
• 136 Lin H R, Bauer-Wu S M. Psycho-spiritual well-being in patients with advanced cancer: an integrative review of the literature.  J Adv Nurs. 2003;  44 69-80
• 137 Sand L, Strang P. Existential loneliness in a palliative home care setting.  J Palliat Med. 2006;  9 1376-1387
• 138 Osse B HP, Vernooij-Dassen M JFJ, Schadé E, Grol R PTM. The problems experienced by patients with cancer and their needs for palliative care.  Support Care Cancer. 2005;  13 722-732
• 139 Henoch I, Bergman B, Gustafsson M, Gaston-Johansson F, Danielson E. The impact of symptoms, coping capacity, and social support on quality of life experience over time in patients with lung cancer.  J Pain Symptom Manage. 2007;  34 370-379